Michael Panzara
Rodin Therapeutics (United States)(US)
Publications by Year
Research Areas
Multiple Sclerosis Research Studies, Polyomavirus and related diseases, Monoclonal and Polyclonal Antibodies Research, Rheumatoid Arthritis Research and Therapies, Immunotherapy and Immune Responses
Most-Cited Works
- → A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis(2006)3,309 cited
- → B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis(2008)2,374 cited
- → Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis(2006)1,330 cited
- → Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial(2012)1,191 cited
- → Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial(2012)1,184 cited
- → Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial(2008)526 cited